198 related articles for article (PubMed ID: 38049318)
21. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.
Eichenauer DA; Thielen I; Haverkamp H; Franklin J; Behringer K; Halbsguth T; Klimm B; Diehl V; Sasse S; Rothe A; Fuchs M; Böll B; von Tresckow B; Borchmann P; Engert A
Blood; 2014 Mar; 123(11):1658-64. PubMed ID: 24478403
[TBL] [Abstract][Full Text] [Related]
22. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
[TBL] [Abstract][Full Text] [Related]
23. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
24. Eprenetapopt Plus Azacitidine in
Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
[TBL] [Abstract][Full Text] [Related]
25. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
26. [Clinical Efficacy and Survival Analysis of Adult Patients with Acute Myeloid Leukemia after Microtransplantation].
Huang YJ; Zhang JH; Dong CX; Kang JM; Hou YF; Zhang YF; Qi K; Yang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1361-1368. PubMed ID: 36208236
[TBL] [Abstract][Full Text] [Related]
27. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
28. [A long-term follow-up study of 82 children with acute myeloid leukemia].
Ruan M; Qi BQ; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):730-734. PubMed ID: 30293275
[No Abstract] [Full Text] [Related]
29. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
31. Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry.
Yoo KH; Kim HJ; Min YH; Hong DS; Lee WS; Kim HJ; Shin HJ; Park Y; Lee JH; Kim H
PLoS One; 2021; 16(5):e0251011. PubMed ID: 33961640
[TBL] [Abstract][Full Text] [Related]
32. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
[TBL] [Abstract][Full Text] [Related]
33. Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.
Ruutu T; Hänninen A; Järventie G; Koistinen P; Koivunen E; Kätkä K; Nousiainen T; Oksanen K; Pelliniemi TT; Remes K; Timonen T; Volin L; Elonen E
Leuk Res; 1997 Feb; 21(2):133-8. PubMed ID: 9112430
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.
Lobe I; Rigal-Huguet F; Vekhoff A; Desablens B; Bordessoule D; Mounier C; Ferrant A; Sanz M; Fey M; Chomienne C; Chevret S; Degos L; Fenaux P;
Leukemia; 2003 Aug; 17(8):1600-4. PubMed ID: 12886249
[TBL] [Abstract][Full Text] [Related]
35. Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases.
Iwakiri R; Ohta M; Mikoshiba M; Tsutsumi H; Kumakawa T; Mori M
Int J Hematol; 2002 Jan; 75(1):45-50. PubMed ID: 11843290
[TBL] [Abstract][Full Text] [Related]
36. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
38. Low dose of homoharringtonine and cytarabine-based priming induction regimens for patients with
Wang F; Xu W; Liu L; Ren X; Liu P; Zheng L; Zhang H; Zhang S; Xu Y; Guo Z
Hematology; 2021 Dec; 26(1):1040-1045. PubMed ID: 34895093
[TBL] [Abstract][Full Text] [Related]
39. [Treatment responses, outcomes, and prognostic factors associated with them in patients with secondary acute myeloid leukemia].
Ma L; Zhao T; Chen YY; Jiang H; Xu LP; Zhang XH; Wang Y; Sun YQ; Mo XD; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):124-131. PubMed ID: 36948866
[No Abstract] [Full Text] [Related]
40. [Analysis of efficacy and prognosis of induction chemotherapy in 76 elderly patients with acute myeloid leukemia (non-APL)].
Yang H; Niu JH; Zhu CY; Zhang Q; Zhu HY; Yao ZL; Zhou MH; Wang QS; Yu L; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):957-64. PubMed ID: 25130810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
